Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Regulatory Peptides
- Vol. 128 (2) , 135-148
- https://doi.org/10.1016/j.regpep.2004.07.014
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical developmentDrugs of the Future, 2001
- Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1997
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoJournal of Clinical Endocrinology & Metabolism, 1995
- Glucagon-Like Peptide-1 and Glucose-Dependent Insulin-Releasing Polypeptide Plasma Levels in Response to NutrientsDigestion, 1995
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomyDigestive Diseases and Sciences, 1991
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.Journal of Clinical Investigation, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- The incretin concept todayDiabetologia, 1979